Introducción

hronic obstructive pulmonary disease is both an obstructive and inflammatory disease. Mesenchymal stem cell (MSC) therapy has shown early promise to modulate inflammation and improve lung function. The therapy has limitations resulting from cell loss and sub-optimal delivery. Even when MSC therapy demonstrates a clinical benefit, there are questions related to redosing if the clinical improvement decreases. Our goal was to develop a redosing strategy for MSC therapy in patients with COPD.